Healthcare Takes A Big Step Forward With The Help of A.I.

To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.

Click here to learn more about the booming eHealth industry - and see which microcap will be at the

CRVS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 31.30%

Insider Buying (Last 12 Months): $1,033,906.82

Insider Selling (Last 12 Months): $0.00

Corvus Pharmaceuticals Insider Trading History Chart

Corvus Pharmaceuticals Share Price & Price History

^$4.32

▼ -3.07 (-41.54%)

As of 12/18/2024 03:46 PM ET

Days: 30 | 90 | 365

This drone stock is setting up to transform medical supply delivery

From The Tomorrow Investor | Ad

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth

Corvus Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/6/2024	Richard A. Miller	CEO	Buy	577,634	$1.73	$999,306.82	577,634
5/6/2024	William Benton Jones	Insider	Buy	20,000	$1.73	$34,600.00	153,773
5/15/2023	Linda Grais	Director	Buy	10,000	$2.45	$24,500.00	10,000
12/20/2022	William Benton Jones	Insider	Buy	20,000	$0.79	$15,800.00	133,773
12/13/2022	Leiv Lea	CFO	Buy	30,000	$0.74	$22,200.00	129,238
12/13/2022	Richard A. Miller	CEO	Buy	50,000	$0.74	$37,000.00	1,480,119
9/28/2022	Richard A. Miller	CEO	Buy	25,000	$0.76	$19,000.00	1,394,405
9/20/2022	Richard A. Miller	CEO	Buy	20,000	$0.81	$16,200.00	1,369,405
6/27/2022	Richard A. Miller	CEO	Buy	5,000	$1.00	$5,000.00	1,349,405
6/24/2022	Richard A. Miller	CEO	Buy	5,000	$1.03	$5,150.00	1,344,405
6/6/2022	Richard A. Miller	CEO	Buy	890	$1.01	$898.90	1,339,405
6/2/2022	Richard A. Miller	CEO	Buy	5,000	$0.98	$4,900.00	1,338,515
3/31/2022	Richard A. Miller	CEO	Buy	15,000	$1.64	$24,600.00
3/17/2022	Richard A. Miller	CEO	Buy	5,000	$1.59	$7,950.00
3/16/2022	Leiv Lea	CFO	Buy	35,160	$1.54	$54,146.40
3/15/2022	Richard A. Miller	CEO	Buy	25,000	$1.47	$36,750.00

Healthcare Takes A Big Step Forward With The Help of A.I.

From Wall Street Star | Ad

Click here to learn more about the booming eHealth industry - and see which microcap will be at the

SEC Filings (Institutional Ownership Changes) for Corvus Pharmaceuticals (NASDAQ:CRVS)

46.64% of Corvus Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Corvus Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/20/2024	Virtu Financial LLC	15,694	$83K	0.0%	N/A	0.024%
11/16/2024	Geode Capital Management LLC	563,009	$2.97M	0.0%	+22.4%	0.900%
11/15/2024	XTX Topco Ltd	14,086	$74K	0.0%	N/A	0.023%
11/15/2024	Jane Street Group LLC	50,221	$0.27M	0.0%	N/A	0.080%
11/15/2024	State Street Corp	178,246	$0.94M	0.0%	+48.2%	0.285%
11/15/2024	Point72 Asset Management L.P.	5,562,729	$29.37M	0.1%	-6.7%	8.893%
11/12/2024	Nwam LLC	10,050	$53K	0.0%	N/A	0.016%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	137,031	$0.72M	0.0%	+64.7%	0.219%
11/6/2024	OneDigital Investment Advisors LLC	10,000	$53K	0.0%	-31.3%	0.016%
11/6/2024	Towerview LLC	117,500	$0.62M	0.4%	-70.6%	0.188%
11/6/2024	Oppenheimer & Co. Inc.	16,947	$89K	0.0%	N/A	0.027%
10/10/2024	Avity Investment Management Inc.	27,580	$0.15M	0.0%	+138.2%	0.044%
9/16/2024	Cubist Systematic Strategies LLC	24,364	$44K	0.0%	N/A	0.039%
8/19/2024	Point72 Asset Management L.P.	5,964,510	$10.86M	0.0%	N/A	9.535%
8/14/2024	Cubist Systematic Strategies LLC	24,364	$44K	0.0%	N/A	0.039%
8/14/2024	Marshall Wace LLP	74,559	$0.14M	0.0%	N/A	0.119%
8/14/2024	Samlyn Capital LLC	6,123,021	$11.14M	0.2%	+160.7%	9.789%
8/9/2024	Renaissance Technologies LLC	563,932	$1.03M	0.0%	-11.5%	0.902%
7/26/2024	Towerview LLC	400,000	$0.73M	0.5%	+4.6%	0.639%
5/16/2024	BVF Inc. IL	361,406	$0.64M	0.0%	-73.6%	0.737%
5/10/2024	Vanguard Group Inc.	1,493,357	$2.66M	0.0%	+10.6%	3.045%
5/7/2024	Towerview LLC	382,500	$0.68M	0.5%	-12.4%	0.780%
2/1/2024	Towerview LLC	436,873	$0.77M	0.5%	+27.6%	0.891%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	70,883	$0.10M	0.0%	-16.0%	0.145%
11/4/2023	Towerview LLC	342,478	$0.50M	0.3%	+67.1%	0.699%
9/8/2023	Tucker Asset Management LLC	12,871	$29K	0.0%	N/A	0.026%
8/22/2023	CHI Advisors LLC	200,000	$0.46M	0.1%	-91.5%	0.408%
8/11/2023	MYDA Advisors LLC	100,000	$0.23M	0.1%	N/A	0.204%
8/7/2023	Acadian Asset Management LLC	58,069	$0.13M	0.0%	-55.9%	0.125%
8/3/2023	Towerview LLC	205,000	$0.47M	0.3%	N/A	0.440%
7/27/2023	Virtu Financial LLC	25,542	$58K	0.0%	+32.0%	0.055%
5/11/2023	CHI Advisors LLC	2,339,402	$2.13M	0.6%	-1.9%	5.024%
2/14/2023	Discovery Capital Management LLC CT	548,727	$0.47M	0.1%	N/A	1.179%
11/17/2022	Telemetry Investments L.L.C.	522,009	$0.43M	0.5%	+13.5%	1.121%
10/18/2022	Bailard Inc.	39,998	$33K	0.0%	N/A	0.086%
4/20/2022	Jackson Square Capital LLC	63,773	$0.11M	0.0%	N/A	0.137%
4/13/2022	Hikari Power Ltd	49,959	$82K	0.0%	+150.3%	0.107%
2/15/2022	Coastal Bridge Advisors LLC	24,000	$58K	0.0%	N/A	0.052%
2/14/2022	Point72 Asset Management L.P.	795,000	$1.92M	0.0%	+38.3%	1.708%
2/10/2022	Acadian Asset Management LLC	81,166	$0.19M	0.0%	+96.9%	0.174%
11/22/2021	EcoR1 Capital LLC	2,081,077	$10.07M	0.4%	-41.9%	4.471%
11/16/2021	Squarepoint Ops LLC	19,954	$97K	0.0%	N/A	0.043%
11/16/2021	Tang Capital Management LLC	3,749,379	$18.15M	3.8%	N/A	8.055%
11/16/2021	Two Sigma Investments LP	140,455	$0.68M	0.0%	-54.6%	0.302%
11/16/2021	Two Sigma Securities LLC	22,789	$0.11M	0.0%	N/A	0.049%
11/16/2021	Telemetry Investments L.L.C.	196,168	$0.95M	1.3%	-25.7%	0.421%
11/16/2021	VR Adviser LLC	3,427,461	$16.59M	2.1%	N/A	7.363%
11/16/2021	BVF Inc. IL	1,370,947	$6.64M	0.3%	-62.7%	2.945%
11/16/2021	CHI Advisors LLC	165,927	$0.80M	0.2%	-76.9%	0.356%
11/15/2021	Point72 Asset Management L.P.	575,000	$2.78M	0.0%	N/A	1.235%
11/15/2021	Pura Vida Investments LLC	734,268	$3.55M	0.1%	N/A	1.577%
11/15/2021	Zacks Investment Management	10,000	$48K	0.0%	N/A	0.021%
11/12/2021	Affinity Asset Advisors LLC	50,000	$0.24M	0.1%	N/A	0.107%
11/12/2021	Renaissance Technologies LLC	614,370	$2.97M	0.0%	-6.6%	1.320%
11/12/2021	DC Investments Management LLC	50,709	$0.25M	0.5%	N/A	0.109%
11/12/2021	MYDA Advisors LLC	60,000	$0.29M	0.1%	N/A	0.129%
11/12/2021	Geode Capital Management LLC	210,243	$1.02M	0.0%	+10.9%	0.452%
11/12/2021	Artal Group S.A.	500,000	$2.42M	0.1%	N/A	1.074%
11/9/2021	BlackRock Inc.	100,451	$0.49M	0.0%	-23.3%	0.216%
11/5/2021	Lindbrook Capital LLC	14,000	$68K	0.0%	N/A	0.033%
8/17/2021	BVF Inc. IL	3,678,626	$9.82M	0.4%	+13.9%	8.672%
8/16/2021	Telemetry Investments L.L.C.	263,975	$0.71M	1.0%	+6.0%	0.622%
8/16/2021	State Street Corp	29,600	$79K	0.0%	N/A	0.070%
8/13/2021	Renaissance Technologies LLC	658,070	$1.76M	0.0%	-0.8%	1.551%
8/13/2021	Northern Trust Corp	59,262	$0.16M	0.0%	+56.5%	0.140%
8/13/2021	Laurion Capital Management LP	59,150	$0.16M	0.0%	-79.0%	0.139%
8/13/2021	Algert Global LLC	19,737	$53K	0.0%	-53.9%	0.047%
8/13/2021	Natixis	27,900	$74K	0.0%	+69.1%	0.066%
8/13/2021	Geode Capital Management LLC	189,541	$0.51M	0.0%	+27.4%	0.447%
8/13/2021	Vanguard Group Inc.	1,109,218	$2.96M	0.0%	+10.9%	2.615%
8/12/2021	Dimensional Fund Advisors LP	395,829	$1.06M	0.0%	-5.0%	0.933%
8/11/2021	CHI Advisors LLC	719,132	$1.92M	0.4%	+5.9%	1.695%
5/18/2021	BVF Inc. IL	3,229,426	$9.95M	0.4%	+66.1%	8.430%
5/18/2021	Millennium Management LLC	99,096	$0.31M	0.0%	-18.5%	0.259%
5/18/2021	Orbimed Advisors LLC	8,053,298	$24.80M	0.2%	+19.0%	21.021%
5/17/2021	Ikarian Capital LLC	100,000	$0.31M	0.0%	N/A	0.261%
5/17/2021	Goldman Sachs Group Inc.	30,804	$95K	0.0%	-62.3%	0.080%
5/14/2021	Laurion Capital Management LP	282,132	$0.87M	0.0%	N/A	0.736%
5/14/2021	Dimensional Fund Advisors LP	416,649	$1.28M	0.0%	-4.5%	1.088%
5/14/2021	Algert Global LLC	42,857	$0.13M	0.0%	+177.1%	0.112%
5/13/2021	Renaissance Technologies LLC	663,470	$2.04M	0.0%	-16.8%	1.732%
5/12/2021	Northern Trust Corp	37,878	$0.12M	0.0%	+28.6%	0.099%
5/12/2021	Geode Capital Management LLC	148,834	$0.46M	0.0%	+34.5%	0.388%
5/11/2021	Mercer Global Advisors Inc. ADV	10,500	$32K	0.0%	N/A	0.027%
5/11/2021	Acadian Asset Management LLC	20,936	$64K	0.0%	-77.4%	0.055%
5/10/2021	GSA Capital Partners LLP	95,613	$0.29M	0.0%	N/A	0.250%
5/10/2021	Bank Julius Baer & Co. Ltd Zurich	336,748	$1.04M	0.0%	N/A	0.879%
5/7/2021	BlackRock Inc.	77,668	$0.24M	0.0%	+11.3%	0.203%
5/4/2021	Envestnet Asset Management Inc.	10,500	$32K	0.0%	N/A	0.027%
2/18/2021	Truist Financial Corp	21,000	$75K	0.0%	N/A	0.075%
2/12/2021	CHI Advisors LLC	490,877	$1.75M	0.5%	-15.8%	1.749%
2/10/2021	Renaissance Technologies LLC	797,070	$2.84M	0.0%	-8.9%	2.840%
2/5/2021	BlackRock Inc.	69,810	$0.25M	0.0%	-56.8%	0.249%
1/25/2021	Golden Green Inc.	19,539	$70K	0.1%	N/A	0.070%
11/13/2020	Morgan Stanley	32,746	$0.13M	0.0%	+117.7%	0.117%
11/6/2020	BlackRock Inc.	161,549	$0.65M	0.0%	-48.0%	0.576%

Data available starting January 2016

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Today's Range

Now: $4.32

$3.77

$5.20

50 Day Range

MA: $8.18

$5.81

$9.56

52 Week Range

Now: $4.32

$1.30

$10.00

Volume

12,316,742 shs

Average Volume

455,778 shs

Market Capitalization

$277.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Who are the company insiders with the largest holdings of Corvus Pharmaceuticals?: Corvus Pharmaceuticals' top insider shareholders include:
Richard A Md Miller (CEO)
William Benton Jones (Insider)
Linda Grais (Director)
Learn More about top insider investors at Corvus Pharmaceuticals.
Who are the major institutional investors of Corvus Pharmaceuticals?: Corvus Pharmaceuticals' top institutional shareholders include:
Point72 Asset Management L.P. — 8.89%
Geode Capital Management LLC — 0.90%
State Street Corp — 0.28%
Connor Clark & Lunn Investment Management Ltd. — 0.22%
Towerview LLC — 0.19%
Jane Street Group LLC — 0.08%
Learn More about top institutional investors of Corvus Pharmaceuticals stock.
Which major investors are selling Corvus Pharmaceuticals stock?: Within the previous quarter, CRVS stock was sold by these institutional investors:
Point72 Asset Management L.P.
Towerview LLC
OneDigital Investment Advisors LLC
Which major investors are buying Corvus Pharmaceuticals stock?: During the last quarter, CRVS stock was acquired by institutional investors including:
Geode Capital Management LLC
State Street Corp
Connor Clark & Lunn Investment Management Ltd.
Jane Street Group LLC
Oppenheimer & Co. Inc.
Avity Investment Management Inc.
Virtu Financial LLC
Wolverine Trading LLC
Within the previous year, these company insiders have bought Corvus Pharmaceuticals stock:
Richard A Md Miller (CEO)
William Benton Jones (Insider)
Linda Grais (Director)
Learn More investors buying Corvus Pharmaceuticals stock.

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol